10-Q: Dror Ortho-Design Faces Cash Crunch, Delays FDA Approval

Dror Ortho-Design reports significant operating losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, while also delaying its FDA submission for its novel orthodontic platform.

Summary

• Dror Ortho-Design, Inc. filed its quarterly report for the period ended March 31, 2026.
• The company continues to operate at a loss, with a net loss of $638,666 for the quarter, contributing to an accumulated deficit of $22,690,209.
• Cash reserves have significantly decreased, with a balance of $23,802 as of March 31, 2026, down from $228,540 at the end of 2025, leading to substantial doubt about the company's ability to continue as a going concern.
• Operating expenses decreased by 13% to $497,194 from $576,426 in the prior year's quarter, primarily due to a 51% reduction in research and development expenses.
• General and administrative expenses increased by 21% to $378,784.
• The company has not yet filed its 510(k) submission for its new orthodontic Platform with the FDA and is preparing for this submission, indicating a delay in its commercialization timeline.
• The company received $200,000 in bridge financing during the quarter, and subsequently raised an additional $275,000 in bridge notes on April 28, 2026.
• A new Chief Financial Officer, Ran Israeli, was appointed effective May 1, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the significant increase in net loss, drastic reduction in cash reserves, and continued uncertainty regarding FDA approval and future funding, all pointing to a precarious financial situation.

Positives

• Research and development expenses decreased by 51% to $118,410, indicating a potential focus on cost management.
• The company secured $200,000 in bridge financing during the quarter and an additional $275,000 in bridge notes shortly after the period end, providing some short-term liquidity.
• A new CFO, Ran Israeli, with extensive financial leadership experience, has been appointed, potentially bringing improved financial management.
• The company has several patents for its technology and its predecessor's system received FDA clearance in April 2020.

Negatives

• The company incurred a net loss of $638,666 for the quarter, exacerbating its accumulated deficit to $22,690,209.
• Cash and cash equivalents plummeted to $23,802 as of March 31, 2026, from $228,540 at the end of 2025, raising substantial doubt about the company's ability to continue as a going concern.
• General and administrative expenses increased by 21% to $378,784.
• The company has not yet filed its 510(k) submission for its new orthodontic Platform with the FDA, indicating a delay in product commercialization.
• The company is heavily reliant on external financing, with no assurance of future capital raises.
• The company has not yet generated material revenues and is still in the development stage.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to its recurring operating losses, negative working capital, and dependence on external financing.
• The company has not yet filed its 510(k) submission for the Platform with the FDA, and failure to obtain timely marketing authorization could adversely affect its ability to grow.
• The company faces competition from large, internationally established aligner companies.
• The company's success depends on its proprietary technology and its ability to enforce intellectual property rights.
• The company's operations are located in Israel, and ongoing regional conflicts, while currently immaterial, could potentially impact operations.
• The company may not be able to raise additional capital on favorable terms, which could force it to delay, reduce, or eliminate research and development programs or cease operations.
• The company's products and technologies may not be accepted by commercial consumers.
• The company is subject to extensive and costly regulations, including those from the FDA and other authorities, with potential for substantial penalties for non-compliance.

Future Outlook

The company intends to spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection. However, the company anticipates continued operating losses and is dependent on raising additional capital to fund operations and growth, with no assurance of success.

Management Comments

• Management believes that recent rapid advancements in technology have made traditional aligner solutions no longer the most effective treatment option for smile correction.
• Management believes that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions; rather, they can get a perfect smile discreetly and hassle-free even while they sleep with our FDA-cleared proprietary solution.
• Management states that the company has not yet generated any material revenues and has suffered recurring losses from operations with an accumulated deficit of $22,690,209 and negative working capital of $3,144,544 as of March 31, 2026, raising substantial doubt as to the company's ability to continue as a going concern.
• Management will continue to monitor events in the region and their effect on the Company's financial position and results of operations.

Industry Context

StockSavvy.ai notes that Dror Ortho-Design is operating in the competitive orthodontic aligner market, aiming to differentiate itself with a novel, AI-based platform that promises discreet and less painful treatment. However, the company faces significant hurdles in achieving FDA clearance for its updated platform and generating revenue, while established players dominate the market.

Comparison to Industry Standards

• The company's R&D expenses as a percentage of its (non-existent) revenue are not applicable as it has no revenue. However, its operating expenses of $497,194 for the quarter are substantial relative to its cash balance.
• The company's net loss of $638,666 for the quarter is a significant concern for a company in the medical device development stage, especially when compared to companies that have achieved commercialization and revenue generation.
• The company's cash burn rate of $404,268 for the quarter, without corresponding revenue, highlights a critical need for immediate and substantial funding to sustain operations, a situation not uncommon for early-stage biotech or medtech firms but concerning given the lack of revenue.

Management Changes

Legal Proceedings

• As of the date of filing, the company is not a party to any material litigation, nor is it aware of any such threatened or pending litigation.

Related Party Transactions

• Accrued executive salaries of $153,380 as of March 31, 2026, were unpaid due to cash management considerations.
• Consulting services paid to director Yehuda Englander amounted to $11,026 for the three months ended March 31, 2026, with accrued expenses of $3,633 related to this agreement.
• The company issued 20,000,000 shares of Common Stock valued at $200,000 to American Academy of Facial Esthetics LLC (AAFE) as prepayment for marketing and promotional services.

Stakeholder Impact

• Shareholders face continued dilution risk due to the need for further capital raises and potential for significant value erosion given the company's financial state and lack of revenue.
• Employees may face uncertainty regarding job security due to the going concern issues and potential need to reduce operations.
• Creditors and noteholders face increased risk of non-payment if the company cannot secure additional funding or achieve commercial viability.
• Suppliers may face payment delays or demands for upfront payment due to the company's liquidity constraints.

Next Steps

• Prepare and file the 510(k) submission for the Platform with the FDA.
• Continue research and development activities.
• Explore and secure additional fundraising opportunities to fund operations.
• Monitor the impact of regional conflicts on operations.
• The new CFO will likely focus on financial stability and strategic capital raising.

Key Dates

Recommendation

The company's severe liquidity crisis, evidenced by a critically low cash balance and substantial doubt about its going concern status, coupled with ongoing operating losses and delays in FDA approval, presents an extremely high-risk investment profile. The need for continuous capital raises suggests significant future dilution for existing shareholders. Without a clear path to revenue generation and profitability, the risk of complete capital loss is substantial.

Keywords

Dror Ortho-Design, orthodontic platform, SEC filing, Form 10-Q, financial statements, going concern, FDA approval, R&D expenses, bridge financing, CFO appointment